We're taking a closer look at Haleon today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 1.6% compared to 1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:
-
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
-
Haleon has moved 4.7% over the last year compared to 23.6% for the S&P 500 -- a difference of -18.9%
-
HLN has an average analyst rating of buy and is -12.69% away from its mean target price of $9.3 per share
-
Its trailing 12 month earnings per share (EPS) is $0.34
-
Haleon has a trailing 12 month Price to Earnings (P/E) ratio of 23.9 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $0.44 and its forward P/E ratio is 18.5
-
The company has a Price to Book (P/B) ratio of 4.56 in contrast to the S&P 500's average ratio of 2.95
-
Haleon is part of the Consumer Discretionary sector, which has an average P/E ratio of 22.96 and an average P/B of 4.24
-
Haleon has on average reported free cash flows of $1.74 Billion over the last four years, during which time they have grown by an an average of 13.6%